Rieger M, Hilgert I, Kristofová H, Vlachov K
Folia Biol (Praha). 1979;25(4):220-30.
In the B10.D2 leads to B10.D2(M504) strain combination (H-2D incompatibility), 20--40% of skin allografts survive for more than 100 days in ALS-treated recipients. Allograft tolerance in ALS-treated recipients could not be abolished by adoptively transferred normal or immune syngeneic spleen cells, but it could be adoptively transferred by spleen or lymph node cells to sublethally irradiated syngeneic mice. The suppressive activity of transferred cell population markedly declined after treatment with anti Thy-1.2 serum and complement. Cells with suppressor activity could be demonstrated by adoptive transfers as early as 5 days after skin grafting and ALS treatment. The results showed that the long-term allograft-promoting effect of ALS was caused not only by a decrease in the graft-rejection cell potential of the recipients (as demonstrated by other authors earlier) but also by the activation of a T cell-mediated suppressor mechanism.
在B10.D2到B10.D2(M504)品系组合(H-2D不相容)中,20%至40%的皮肤同种异体移植物在接受抗淋巴细胞血清(ALS)治疗的受体中存活超过100天。接受ALS治疗的受体中的同种异体移植耐受性不能通过过继转移正常或免疫同基因脾细胞而被消除,但脾或淋巴结细胞可以将其过继转移给亚致死剂量照射的同基因小鼠。在用抗Thy-1.2血清和补体处理后,转移细胞群体的抑制活性显著下降。早在皮肤移植和ALS治疗后5天,通过过继转移就可以证明具有抑制活性的细胞。结果表明,ALS的长期同种异体移植促进作用不仅是由于受体的移植排斥细胞潜能降低(如其他作者先前所示),还由于T细胞介导的抑制机制的激活。